Five‐year outcomes after iodine‐125 seed brachytherapy for low‐risk prostate cancer at three cancer centres in the UK. (2nd December 2013)

• Record Type: Journal Article
• Authors: Dickinson, Peter D.; Malik, Jahangeer; Mandall, Paula; Swindell, Ric; Bottomley, David; Hoskin, Peter; Logue, John P.; Wylie, James P.
• Is Part Of: BJU international. Volume 113:Number 5(2014:May)
• Page Start: 748
• Page End: 753
• Publication Date: 2013-12-02
• Subjects: Genitourinary organs -- Diseases -- Periodicals; Genitourinary organs -- Surgery -- Periodicals; Urology -- Periodicals; 616.6
• DOI: 10.1111/bju.12358
• Languages: English
• ISSNs: 1464-4096

Abstract

<abstract abstract-type="main"> <title> <x xml:space="preserve">Abstract</x> </title> <sec id="bju12358-sec-0001" sec-type="section"> <title>Objective</title> <p> <list id="bju12358-list-0001" list-type="bullet"> <list-item> <p>To report the outcomes of >1000 men with low‐risk prostate cancer treated with low‐dose‐rate (LDR) brachytherapy at three large UK cancer centres.</p> </list-item> </list> </p> </sec> <sec id="bju12358-sec-0002" sec-type="section"> <title>Patients and Methods</title> <p> <list id="bju12358-list-0002" list-type="bullet"> <list-item> <p>A total of 1038 patients with low‐risk prostate cancer (prostate‐specific antigen [PSA] ≤10 ng/mL, Gleason score 6, ≤T2b disease) were treated with LDR iodine 125 (I‐125) brachytherapy between 2002 and 2007.</p> </list-item> <list-item> <p>Patients were treated at three UK centres.</p> </list-item> <list-item> <p>PSA and clinical follow‐up was performed at each centre.</p> </list-item> <list-item> <p>Biochemical recurrence‐free survival was reported for the cohort.</p> </list-item> </list> </p> </sec> <sec id="bju12358-sec-0003" sec-type="section"> <title>Results</title> <p> <list id="bju12358-list-0003" list-type="bullet"> <list-item> <p>The median (range) PSA follow‐up for the whole group was 5 years (4 months to 9 years).</p> </list-item> <list-item> <p>A total of 79 patients had biochemical failure, defined by a rise in PSA level: 16 patients fulfilled the ASTRO definition of biochemical failure, 25 patients fulfilled the Phoenix definition and 38 patients fulfilled both definitions.</p> </list-item> <list-item> <p>The 5‐year biochemical relapse‐free survival (bRFS) rate was 94.1% by the ASTRO definition and 94.2% by the Phoenix definition.</p> </list-item> <list-item> <p>The absence of neoadjuvant hormone therapy was predictive of inferior biochemical control as defined by the Phoenix definition (P = 0.033).</p> </list-item> </list> </p> </sec> <sec id="bju12358-sec-0004" sec-type="section"> <title>Conclusions</title> <p> <list id="bju12358-list-0004" list-type="bullet"> <list-item> <p>Our prospective multicentre series showed excellent bRFS with LDR I‐125 brachytherapy for patients with low‐risk prostate cancer.</p> </list-item> <list-item> <p>Further work is necessary to define the role of neoadjuvant androgen deprivation therapy in combination with brachytherapy.</p> </list-item> </list> </p> </sec> </abstract>